Skip to Content

BMS 213 (Daklinza 30 mg)

Generic Name: daclatasvir

Pill with imprint BMS 213 is Green, Five-sided and has been identified as Daklinza 30 mg. It is supplied by Bristol-Myers Squibb Company.

Daklinza is used in the treatment of hepatitis c and belongs to the drug class NS5A inhibitors. Daklinza 30 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for BMS 213

Daklinza 30 mg BMS 213

Daklinza

Generic Name:
daclatasvir
Imprint:
BMS 213
Strength:
30 mg
Color:
Green
Shape:
Five-sided
Availability:
Prescription only
Drug Class:
NS5A inhibitors
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Bristol-Myers Squibb Company
National Drug Code (NDC):
00003-0213

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide